My personal estimate is that the the percentage of nurses who have done this is effectively zero (less than one in a thousand with high probability, less than one in ten thousand with moderate probability.)
Further, those who did do it are likely to have read through the whitepaper, and therefore are also likely to get the commercial vaccine, as it covers different epitopes than the radvac vaccine.
Agree it is extremely unlikely that many nurses have done so, and your probabilities seem quite reasonable. I think the main reason why many nurses have declined the vaccine is social signaling—either to maintain their social status within a mostly anti-vaccine peer group, or to maintain credibility with their anti-vaccine patients, who may be reluctant or outright refuse to be treated by a nurse who has been vaccinated because such a nurse is on “the wrong side” and can no longer be trusted. However, a nurse could self-administer the radvac vaccine and get some protection, while still being able to honestly claim they have no plans to get the commercial vaccines.
I hadn’t read the whitepaper yet before my initial post, and after a quick scan it looks like you are correct that radvac covers different epitopes than the commercial vaccines (I haven’t done my own detailed analysis yet). Are you and others planning to take radvac still planning to get a commercial vaccine once you are eligible?
Yes, I still plan to get the commercial vaccine once it’s available to me (likely some time in august.) As I understand it, the commercial vaccines hit different areas of the virus from the ones that radvac selected, improving protection even further.
There is actually an optional peptide for radvac which does cover one of the same regions as the commercial vaccines. I elected not to include it under the assumption I’d be getting it from the commercial vaccine.
My personal estimate is that the the percentage of nurses who have done this is effectively zero (less than one in a thousand with high probability, less than one in ten thousand with moderate probability.)
Further, those who did do it are likely to have read through the whitepaper, and therefore are also likely to get the commercial vaccine, as it covers different epitopes than the radvac vaccine.
Agree it is extremely unlikely that many nurses have done so, and your probabilities seem quite reasonable. I think the main reason why many nurses have declined the vaccine is social signaling—either to maintain their social status within a mostly anti-vaccine peer group, or to maintain credibility with their anti-vaccine patients, who may be reluctant or outright refuse to be treated by a nurse who has been vaccinated because such a nurse is on “the wrong side” and can no longer be trusted. However, a nurse could self-administer the radvac vaccine and get some protection, while still being able to honestly claim they have no plans to get the commercial vaccines.
I hadn’t read the whitepaper yet before my initial post, and after a quick scan it looks like you are correct that radvac covers different epitopes than the commercial vaccines (I haven’t done my own detailed analysis yet). Are you and others planning to take radvac still planning to get a commercial vaccine once you are eligible?
Yes, I still plan to get the commercial vaccine once it’s available to me (likely some time in august.) As I understand it, the commercial vaccines hit different areas of the virus from the ones that radvac selected, improving protection even further.
There is actually an optional peptide for radvac which does cover one of the same regions as the commercial vaccines. I elected not to include it under the assumption I’d be getting it from the commercial vaccine.